P1, N=2, Terminated, Inmune Bio, Inc. | Trial completion date: Jan 2025 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2024 --> Mar 2024; Slow/low Enrollment

15 days ago

Trial completion date • Trial termination • Trial primary completion date

INKmune (primed NK cell therapy)

4ms

Study of INKmune in Patients With mCRPC (CaRe Prostate) (clinicaltrials.gov)

P1/2, N=30, Recruiting, Inmune Bio, Inc. | Not yet recruiting --> Recruiting

4 months ago

Enrollment open • Metastases

INKmune (primed NK cell therapy)

11ms

LAUREL: A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (clinicaltrials.gov)

P1, N=9, Recruiting, Inmune Bio, Inc.

11 months ago

New P1 trial

INKmune (primed NK cell therapy)

over1year

In Vivo Generation of Memory-like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmuneTM (ASH 2022)

INKmune priming increased NK glycolysis and oxidative phosphorylation whilst enhancing mitochondrial respiratory capacity and maintaining glycolytic reserve...The TIML-NK have a distinct phenotypic, proteomic and metabolomic signature which mirrors the activity in vitro and in vivo. This is the first time memory-like NK cells have been generated in vivo without the need for cytokine induction or support and our findings inform the development of more optimal NK cell-based immunotherapeutic strategies for cancer.

over 1 year ago

Preclinical

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD69 (CD69 Molecule)

INKmune (primed NK cell therapy)